All In MedTech

FDA Clearance Tracker · P860004-S453

SynchroMed™ Infusion Systems

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 19, 2025

Approved

Time to decision

80 days

Received Sep 30, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P860004-S453
Device name
SynchroMed™ Infusion Systems
Applicant location
Minneapolis, MN
Received
Sep 30, 2025
Decided
Dec 19, 2025
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P860004

Device type

Device class
Class III

Every decision under product code LKK

FDA's approval statement

As written in FDA's record.

approval for software changes to the Model A810 SynchroMed Clinician Programmer Application

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.